Dexcom Inc
DXCM- Exchange
- Nasdaq
- Industry
- Surgical & Medical Instruments & Apparatus
- SEC CIK
- 0001093557
In the last 90 days, Dexcom Inc insiders filed 0 open-market purchases and 11 sales; 975 institutions reported holding it in 13F filings for Q2 2026, worth $26.0B in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Dexcom Inc insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 11 filings
- 7 insiders, $8.43M in total
- Insiders trading
- 7
- Net value
- −$8.43M
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Dexcom Inc, current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Augustinos Nicholas | Director | 29,293Indirect | Sep 16, 2026 | 4 |
| Brown Michael Jon | EVP Chief Legal Compliance Off | 99,885 | Sep 16, 2026 | 11 |
| Sylvain Jereme M | EVP, Chief Financal Officer | 146,828 | Sep 14, 2026 | 5 |
| Boehnlein Glenn S | Director | 5,841 | Sep 10, 2026 | 1 |
| Stern Sadie | EVP Chief People & Culture Off | 126,043 | Aug 28, 2026 | 5 |
| Leach Jacob Steven | President, CEO, and Director | 418,908 | Aug 25, 2026 | 5 |
| Sayer Kevin R | Executive Chair | 302,214 | Aug 24, 2026 | 6 |
| Heller Bridgette P | Director | 29,570 | Aug 13, 2026 | 5 |
| Foletta Mark G | Director | 48,852Indirect | Aug 4, 2026 | 4 |
| Coleman Jon | EVP, Chief Commercial Officer | 95,450 | Jun 5, 2026 | 3 |
| Altman Steven R | Director | 5,565 | Jun 1, 2026 | 2 |
| Gala Renee D | Director | 12,486 | Jun 1, 2026 | 1 |
| Collins Richard Alexander | Director | 5,605 | Jun 1, 2026 | 4 |
| Malady Kyle | Director | 28,242 | Jun 1, 2026 | 1 |
| Driscoll Rimma | Director | 17,319 | Jun 1, 2026 | 1 |
| Ashley Euan A. | Director | 12,731 | Jun 1, 2026 | 2 |
| Osterloh Albert Frederick IV | Director | 8,691 | Jun 1, 2026 | 2 |
| Topol Eric | Director | 380,545Indirect | May 12, 2025 | 0 |
| Dahut Karen M | Director | 17,779Indirect | May 12, 2025 | 0 |
| Dolan Matthew Vincent | EVP, Strategy & Corporate Dev | 42,044 | Jan 30, 2025 | 0 |
| Kahn Barbara | Director | 22,575Indirect | May 21, 2024 | 0 |
| Lawver Teri L | EVP Chief Commercial Officer | 66,641 | Mar 14, 2024 | 0 |
| Regan Barry J. | EVP Operations | 58,469 | Dec 19, 2023 | 0 |
| Flynn Paul R | EVP Global Revenue | 48,949 | Dec 19, 2023 | 0 |
| Pacelli Steven Robert | EVP Managing Director Dexcom V | 124,775 | Nov 27, 2023 | 0 |
| Naganathan Girish | EVP Chief Technology Officer | 47,725 | Nov 27, 2023 | 0 |
| Selvaraj Shelly Ramasamy | SVP Chief Information Officer | 48,453 | Sep 12, 2023 | 0 |
| Skyler Jay S | Director | 63,348Indirect | May 22, 2023 | 0 |
| Balo Andrew K | EVP Regulatory Strategy Clinic | 50,908 | Mar 14, 2023 | 0 |
| Abbey Donald | EVP Global Business Services I | 208,023 | Mar 14, 2023 | 0 |
| Patterson Chad | EVP Global Marketing | 13,675 | May 10, 2022 | 0 |
| Shrishrimal Sumi | SVP Chief Risk Officer | 13,789 | Mar 10, 2022 | 0 |
| Murphy Patrick Michael | EVP, Chief Legal Officer | 16,254 | Sep 13, 2021 | 0 |
| Blackford Quentin S. | Chief Operating Officer | 19,280 | Sep 10, 2021 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Aug 25, 2021 (view filing) | Aug 23 | 2 days | Pacelli Steven RobertManaging Dir., Dexcom Ventures | SSale | −1.08K | $516.40 | −$556.7K | −2.1%49.1K after | 4 lots |
| Aug 4, 2021 (view filing) | Aug 3 | 1 day | Balo Andrew K* | SSale | −2.76K | $515.87 | −$1.42M | −20.6%10.7K after | 8 lots |
| Aug 2, 2021 (view filing) | Jul 30 | 3 days | Leach Jacob StevenEVP Chief Technology Officer | SSale | −12.1K | $476.70 | −$5.76M | −14.6%70.6K after | |
| Jul 27, 2021 (view filing) | Jul 26 | 1 day | Murphy Patrick MichaelEVP, Chief Legal Officer | SSale | −500 | $458.79 | −$229.4K | −2.7%17.7K after | |
| Jul 27, 2021 (view filing) | Jul 23 | 4 days | Pacelli Steven RobertManaging Dir., Dexcom Ventures | SSale | −1.08K | $452.18 | −$487.9K | −2.1%50.2K after | 2 lots |
| Jul 16, 2021 (view filing) | Jul 16 | Same day | Shrishrimal SumiSVP Chief Risk Officer | SSale | −400 | $450.00 | −$180.0K | −3.1%12.6K after | |
| Jul 8, 2021 (view filing) | Jul 6 | 2 days | Balo Andrew K* | SSale | −2.97K | $430.14 | −$1.28M | −18.2%13.4K after | 4 lots |